Clinical and Molecular Characterization of Advanced Hepatocellular Carcinoma: Analysis of Therapeutic Responses Across Multiple Treatment Regimens

Hepatocellular carcinoma (HCC) is a type of liver cancer that affects thousands of people around the world each year. HCC is especially concerning because it is frequently detected when it has already spread, and treatment options are more limited.
To help improve outcomes for people with this cancer, doctors need better ways to understand how the disease behaves and which treatments will work best for each individual patient. That’s where biomarkers come in. Biomarkers are measurable indicators in the body that can give doctors clues about the disease, such as how far it has progressed or how well a treatment is working. Some biomarkers are related to genes or proteins, while others are linked to the immune system. By identifying these markers, we can develop more personalized treatment strategies, allowing doctors to tailor treatments to each patient’s needs.
This study will focus on a range of potential biomarkers to understand which treatments work best for people with advanced HCC. The treatments we’ll look at include Sorafenib, Regorafenib, Doxorubicin, and SHR-1210. Sorafenib and Regorafenib are medications that target specific proteins cancer cells need to grow, while Doxorubicin is a chemotherapy drug that kills cancer cells. SHR-1210 is a type of immunotherapy that helps the body’s immune system recognize and attack cancer cells.
Our research will use data from multiple clinical trials to explore how these treatments affect patient outcomes, including survival rates and how well the cancer responds to the treatment. We will also examine a range of biomarkers, including genetic mutations, protein levels, and immune markers, which could indicate how well the immune system is fighting the cancer. Additionally, we will consider clinical factors such as tumor size, cancer stage, and liver function.
By analyzing all this information together, we aim to improve personalized treatment strategies and predict which patients are most likely to benefit from specific therapies.
Our ultimate goal is to enhance treatment efficacy and inform clinical decision-making for better management of HCC.